Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150

Benzinga Newsdesk www.benzinga.com Positive 71.8%

Neg 0% Neu 0% Pos 71.8%

Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.